natgillin/translations-raw huggingface dataset:
Method for deploying a solar panel assembly (2) according to claim 1, wherein the method comprises the steps of: 
Metoda postavljanja sklopa solarnog panela (2) u skladu s patentnim zahtjevom 1, naznačena time što metoda sadrži korake:
Use of a welded plastic container bag according to any one of claims 1-11 for collection and transport of bulk products, preferably for collection and transport of recyclable goods, more preferably for collection and transport of empty cans and bottles. 
Uporaba zavarene plastične vrećice za spremanje prema bilo kojem od zahtjeva 1-6, za prikupljanje i transport rasutih proizvoda, ponajprije za prikupljanje i transport robe koja se može reciklirati, poželjnije za skupljanje i prijevoz praznih limenki i boca.
A process for manufacturing a welded plastic container bag according to any of claims 1-6, wherein said bag in an upright deployed state has a substantially quadrangular horizontal cross section with a substantially quadrangular base and four side walls, comprising the steps: 
Postupak za proizvodnju zavarene plastične vrećice u skladu s bilo kojim od patentnih zahtjeva 1-6, naznačen time što navedena vrećica u uspravno razmještenom stanju ima značajno četverokutan vodoravni presjek s u osnovi četverokutnom bazom i četiri bočna zida, koji se sastoji od koraka:
providing a gusset folded tube of plastic film having two opposing gusset folds, each gusset fold comprising two outer fold lines and one inner fold line, wherein the front and back side of the gusset folded tube form two opposing side walls of the bag and the two opposing gusset folds form the remaining two opposing side walls; 
pružanje cijevi od plastične folije savijene u obliku cijevi koja ima dva suprotna potporna nabora, svaki preklop se sastoji od dvije vanjske linije nabora i jedne unutarnje linije savijanja, pri čemu je prednja i stražnja strana vrata preklopljena cijev koju čine dvije suprotne bočne stijenke vrećice i dva suprotna potporna nabora oblikovana s preostala dva suprotstavljena bočna zida;
The fusion protein for use of claim 1, wherein the fusion protein increases neurite growth, elongation, branch number, or branch density in a brain of a subject as compared to a control. 
Fuzijski protein za uporabu prema zahtjevu 1, naznačen time što fuzijski protein povećava izrastanje neurita, elongaciju, broj grana, ili gustoću grana u mozgu subjekta u usporedbi s kontrolom.
The fusion protein for uses of claim 1, wherein the fusion protein reduces neuron apoptosis in the brain of a subject as compared to a control. 
Fuzijski protein za uporabe prema zahtjevu 1, naznačen time što fuzijski protein smanjuje apoptozu neurona u mozgu subjekta u usporedbi s kontrolom.
A pharmaceutical formulation for use in the treatment of a CDKL5 deficiency, Rett syndrome, or atypical Rett syndrome caused by a CDKL5 mutation or deficiency, the pharmaceutical formulation comprising: a therapeutically effective amount of the fusion protein as defined in any one of claims 1-7; and a pharmaceutically acceptable carrier. 
Farmaceutska formulacija naznačena time što je za uporabu u liječenju nedostatka CDKL5, Rettovog sindroma ili atipičnog Rettovog sindroma uzrokovanog mutacijom ili nedostatkom CDKL5, pri čemu farmaceutska formulacija sadrži: terapeutski učinkovitu količinu fuzijskog proteina kako je definirano u bilo kojem od zahtjeva 1-7; i farmaceutski prihvatljiv nosač.
release of not more than 10% by weight of the proton pump inhibitor in 120 min in an acid stage comprising 900 ml 0.1N HCl at 100 rpm; and 
otpuštanje najviše 10 % prema težini inhibitora protonske pumpe tijekom 120 minuta u kiseloj fazi s 900 ml 0,1 N HCl pri 100 o/min te
release of not less than 75% by weight of the proton pump inhibitor in 45 min in 900 ml phosphate buffer pH 6.8 at 100 rpm following the acid. 
otpuštanje najmanje 75 % prema težini inhibitora protonske pumpe tijekom 45 minuta u 900 ml fosfatnog pufera pH vrijednosti 6,8 pri 100 o/min nakon primjene kiseline.
The capsule of claim 1 wherein the coating in the second dosage composition delays the release of the proton pump inhibitor from 120 to at least 240 minutes following oral administration. 
Kapsula u skladu s patentnim zahtjevom 1, naznačena time što obloga u pripravku druge doze odgađa otpuštanje inhibitora protonske pumpe sa 120 na najmanje 240 minuta nakon peroralne primjene.
The capsule of claim 6, wherein the time delay agent is one of sodium alginate, glyceryl monostearate, glyceryl distearate, acrylic acids, celluloses or combinations thereof. 
Kapsula u skladu s patentnim zahtjevom 6, naznačena time što se tvar koja odgađa otpuštanje sastoji od natrijeva alginata, gliceril monostearata, gliceril distearata, akrilnih kiselina, celuloza ili kombinacija navedenog.
The capsule of claim 1 wherein at least 70% by weight of the at least two antibiotics are released between 5 and 120 minutes following oral administration; and at least 70% by weight of the proton inhibitor is released between 120 and 240 min following oral administration. 
Kapsula u skladu s patentnim zahtjevom 1, naznačena time što se najmanje 70 % prema težini barem dvaju antibiotika otpušta između 5 i 120 minuta nakon peroralne primjene te se najmanje 70 % prema težini protonskog inhibitora otpušta između 120 i 240 minuta nakon peroralne primjene.
The capsule of claim 1 comprising rifabutin, amoxicillin and omeprazole. 
Kapsula u skladu s patentnim zahtjevom 1, naznačena time što se sastoji od rifabutina, amoksicilina i omeprazola.
The capsule of claim 12, wherein the filler is one of lactose, cellulose, starch, calcium phosphates, calcium carbonate, sugar, or combinations thereof. 
Kapsula u skladu s patentnim zahtjevom 12, naznačena time što se punilo sastoji od laktoze, celuloze, škroba, kalcijevih fosfata, kalcijeva karbonata, šećera ili kombinacija navedenog.
The capsule of claim 12 or claim 13, wherein the disintegrant is one of croscarmellose sodium, carboxymethyl cellulose, sodium starch glycolate, crospovidone or combinations thereof. 
Kapsula u skladu s patentnim zahtjevom 12 ili patentnim zahtjevom 13, naznačena time što se sredstvo za raspadanje sastoji od kroskarmeloza-natrija, karboksimetil-celuloze, natrijeva škrob glikolata, krospovidona ili kombinacija navedenog.
The capsule of any one of claims 12 to 14, wherein the binder is one of starch, cellulose, polyvinylpyrrolidone, xanthan gum, alginic acid, agar or combinations thereof. 
Kapsula u skladu s bilo kojim patentnim zahtjevom od 12 do 14, naznačena time što se vezivo sastoji od škroba, celuloze, polivinilpirolidona, ksantan gume, alginske kiseline, agara ili kombinacija navedenog.
The capsule of any one of claims 12 to 15, wherein the surfactant is one of sodium lauryl sulphate, polyoxyethylene polyoxypropylene glycol, polyethylene glycol, poplypropylene glycol, polyvinyl caprolactam--polyvinyl acetate--polyethylene glycol, macrogolglycerol hydroxystearate or combinations thereof. 
Kapsula u skladu s bilo kojim patentnim zahtjevom od 12 do 15, naznačena time što se površinski aktivna tvar sastoji od natrijeva lauril-sulfata, polioksietilen polioksipropilen glikola, polietilen glikola, polipropilen glikola, polivinil kaprolaktama--polivinil acetata--polietilen glikola, makrogolglicerol hidroksistearata ili kombinacija navedenog.
The capsule of any one of claims 12 to 16, wherein the alkalizing agent is one of meglumine, calcium carbonate, sodium sulfate, sodium bicarbonate or combinations thereof. 
Kapsula u skladu s bilo kojim patentnim zahtjevom od 12 do 16, naznačena time što se alkalizirajuće sredstvo sastoji od meglumina, kalcijeva karbonata, natrijeva sulfata, natrijeva bikarbonata ili kombinacija navedenog.
The capsule of any one of claims 12 to 17, wherein the lubricant is one of magnesium stearate, silicon dioxide, talc, stearic acid, sodium stearyl fumarate, glyceryl behenate or combinations thereof. 
Kapsula u skladu s bilo kojim patentnim zahtjevom od 12 do 17, naznačena time što se mazivo sastoji od magnezijeva stearata, silicijeva dioksida, talka, stearinske kiseline, natrijeva stearil fumarata, gliceril behenata ili kombinacija navedenog.
The capsule of claim 1, wherein the second dosage composition comprises an outer protective layer, an enteric coating and an inner protective layer. 
Kapsula u skladu s patentnim zahtjevom 1, naznačena time što se pripravak druge doze sastoji od vanjskog zaštitnog sloja, enterične obloge i unutrašnjeg zaštitnog sloja.
Process for the preparation of complexes of iron (III) hydroxide and activated glucose syrup, wherein the molecular weight of the complex is in the range of from 100 kDa to 150 kDa, as measured by high performance liquid chromatography-gel permeation chromatography (HPLC-GPC), said process comprising the steps: 
Proces za pripremu kompleksnih spojeva željezo (III) hidroksida i aktiviranog glukoznog sirupa, pri čemu je molekularna težina kompleksa u rasponu od 100 kDa do 150 kDa, kako je izmjereno tekućinskom kromatografijom visokog učinka - gel permeacijskom kromatografijom (HPLC-GPC), naveden process sadrži slijedeće korake:
converting said activated glucose syrup into a complex with iron (III) hydroxide; and 
pretvaranje navedenog aktiviranog glukoznog sirupa u kompleksni spoj sa željezo (III) hidroksidom; i
adding an inorganic base to the reaction mixture of step (iii)(a)until the pH is within a range of from 1.5 to 2.5; and 
dodavanje anorganske baze reakcijskoj mješavini u skladu s korakom (iii)(a) dok pH vrijednost nije raspona od 1,5 do 2,5; i
heating the reaction mixture of step (iii)(b) to a temperature within the range of from 40 to 60°C. 
zagrijavanje reakcijske mješavine u skladu s korakom (iii)(b) do temperature unutar raspona od 40 do 60°C.
Complex of claim 5 or pharmaceutical composition of claim 6 for use as medicament. 
Kompleksni spoj u skladu s patentnim zahtjevom 5 ili farmaceutski spoj u skladu s patentnim zahtjevom 6 za uporabu kao lijek.
Complex of claim 5 or pharmaceutical composition of claim 6 for use in a method of treating iron deficiency in human and animal. 
Kompleksni spoj u skladu s patentnim zahtjevom 5 ili farmaceutski spoj u skladu s patentnim zahtjevom 6 za uporabu u metodi liječenja deficijencije željeza kod ljudi i životinja.
The complex or pharmaceutical composition for use according to claim 8, wherein the treatment comprises parenterally administering said complex of claim 5 or pharmaceutical composition of claim 6. 
Kompleksni spoj ili farmaceutski spoj za uporabu u skladu s patentnim zahtjevom 8, pri čemu liječenje sadrži parenteralnu primjenu navedenog kompleksnog spoja u skladu s patentnim zahtjevom 5 ili farmaceutski spoj u skladu s patentnim zahtjevom 6.
both R7 substituents are the same and are selected from the group consisting of hydrogen, fluoro and methyl; or both R7 substituents are taken together to form together with the common carbon atom to which they are attached a cyclopropyl, cyclobutyl or oxetanyl; 
oba R7 supstituenta su jednaki i odabrani su iz skupine koju čine vodik, fluor i metil; ili oba R7 supstituenta su uzeti zajedno da tvore zajedno sa zajedničkim ugljikovim atomom na koji su vezani ciklopropil, ciklobutil ili oksetanil;
both R8 substituents are the same and are selected from the group consisting of hydrogen and methyl; or both R8 substituents are taken together to form together with the common carbon atom to which they are attached a cyclopropyl, cyclobutyl or oxetanyl; 
oba R8 supstituenta su jednaki i odabrani su iz skupine koju čine vodik i metil; ili oba R8 supstituenta su uzeti zajedno da tvore zajedno sa zajedničkim ugljikovim atomom na koji su vezani ciklopropil, ciklobutil ili oksetanil;
Ar represents phenyl optionally substituted with hydroxy; 
Ar predstavlja fenil po izboru supstituiran s hidroksi;
both R7 substituents are the same and are selected from the group consisting of hydrogen, fluoro and methyl; 
oba R7 supstituenta su jednaki i odabrani su iz skupine koju čine vodik, fluor i metil;
both R8 substituents are the same and are selected from the group consisting of hydrogen and methyl; 
oba R8 supstituenta su jednaki i odabrani su iz skupine koju čine vodik i metil;
Ar represents phenyl; 
Ar predstavlja fenil;
p represents 2. 
p predstavlja 2.
represents and Y represents -CH2-. 
predstavlja i Y predstavlja -CH2-.
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound according to any one of claims 1 to 11. 
Farmaceutski pripravak naznačen time što sadrži farmaceutski prihvatljiv nosač i, kao aktivni sastojak, terapeutski učinkovitu količinu spoja prema bilo kojem od patentnih zahtjeva 1 do 11.
The compound for use according to claim 13 wherein the disease or condition is cancer. 
Spoj za uporabu prema patentnom zahtjevu 13 naznačen time što bolest ili stanje je rak.
The compound for use according to claim 14 wherein the disease or condition is prostate cancer. 
Spoj za uporabu prema patentnom zahtjevu 14 naznačen time što bolest ili stanje je rak prostate.
The crystalline form t of rifaximin according to claim 1, characterized by a tetragonal crystal system, the space group is P41212 and the unit cell parameters are a=b=16.51 (1) Å; c=36,80(1) Å; a=β=γ= 90°; V= 10027(1) Å3. 
Kristalni oblik t rifaksimina u skladu s patentnim zahtjevom 1, naznačen time što ima tetragonski kristal sustav, gdje je prostorna skupina P41212, a parametri jedinične ćelije su a=b=16,51 (1) Å; c=36,80(1) Å; a=β=γ= 90°; V= 10027(1) Å3.
drying the obtained precipitate at a temperature ranging from room temperature to 40°C under a pressure comprised between ambient pressure and under vacuum, for a duration of time ranging from 5 minutes to 1 day, wherein the precipitate before drying is optionally washed with apolar solvent. 
– sušenja dobivenog taloga na temperaturi u rasponu od sobne temperature do 40 °C pod tlakom koji se kreće između tlaka okoliša i vakuuma, u trajanju u rasponu od 5 minuta do 1 dan, gdje se talog prije sušenja može isprati nepolarnim otapalom.
The process of claim 6, wherein the product is dried by means of lyophilisation. 
Postupak u skladu s patentnim zahtjevom 6, naznačen time što se proizvod osuši liofiliziranjem.
A pharmaceutical composition comprising an effective amount of the crystalline form t of rifaximin according to claim 1 together with pharmaceutically acceptable excipients. 
Farmaceutski pripravak, naznačen time što sadrži djelotvornu količinu kristalnog oblika t rifaksimina u skladu s patentnim zahtjevom 1, uz farmaceutski prihvatljive pomoćne tvari.
The pharmaceutical composition according to claim 8, for use in the treatment or the prevention of intestinal infections caused by bacteria Escherichia coli or Clostridium difficile, traveller's diarrhoea, infectious diarrhoea, intestinal disorder as Crohn's disease, irritable bowel syndrome (IBS), enteritis, enterocolitis, diverticulitis, syndrome of the overgrowth of bacteria in the small intestine (SIBO), colitis, pancreatic insufficiency, chronic pancreatitis, hepatic encephalopathy, functional gastrointestinal disorders, functional dyspepsia with diarrhoea, and vaginal infections. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 8, naznačen time što je namijenjen upotrebi u liječenju ili sprječavanju crijevnih infekcija koje uzrokuju bakterije Escherichia coli ili Clostridium difficile, putničkog proljeva, zaraznog proljeva, crijevnog poremećaja poput Crohnove bolesti, sindroma iritabilnih crijeva (IBS), enteritisa, enterokolitisa, divertikulitisa, sindroma prerastanja bakterija u tanko crijevo (SIBO), kolitisa, insuficijencije gušterače, kroničnog pankreatitisa, hepatične encefalopatije, funkcionalnih gastrointestinalnih poremećaja, funkcionalne dispepsije uz proljev, te vaginalnih infekcija.
further comprising: (a-1) reacting compound I-1: in the presence of a solvent, an oxidizing agent, and Catalyst A to form an aldehyde in situ, followed by a condensation in the presence of X-CN and ammonium chloride and a protective reagent to produce compound 1-2: 
koji nadalje sadrži: (a-1) reakciju spoja I-1: u prisutnosti otapala, oksidacijskog sredstva, i Katalizatora A da se dobije aldehid in situ, nakon čega slijedi kondenzacija u prisutnosti X-CN i amonijevog klorida i zaštitnog reagensa da se dobije spoj 1-2: (b-1) reakciju spoja 1-2 u prisutnosti fenil Grignardovog reagensa da se dobije spoj 1-3: pri čemu je X odabran od Na i K.
The process of claim 3, wherein in step (a-1): the solvent is selected from the group consisting of THF, MTBE, CH2Cl2, MeCN, EtOAc, i-PrOAc, Me-THF, hexane, heptane, DMAc, DMF, methyl cyclopentyl ether, toluene and combinations thereof; the oxidizing agent is selected from the group consisting of NaOCl, NaClO2, PhI(OAc)2, hydrogen peroxide, pyridine sulfur trioxide/Et3N/DMSO and a Moffatt variant, PCC, DCC, a Swern oxidation or its variants, TPAP/NMO; and the catalyst is TEMPO or a TEMPO analogue. 
Postupak prema patentnom zahtjevu 3, naznačen time što je u koraku (a-1): otapalo odabrano iz skupa koji sadrži THF, MTBE, CH2Cl2, MeCN, EtOAc, i-PrOAc, Me-THF, heksan, heptan, DMAc, DMF, metil ciklopentil eter, toluen i njihove kombinacije; oksidacijsko sredstvo je odabrano iz skupa koji sadrži NaOCl, NaClO2, PhI(OAc)2, vodikov peroksid, piridin sulfur trioksid/Et3N/DMSO i Moffatt-ovu varijantu, PCC, DCC, Swern-ovu oksidaciju ili njezine varijante, TPAP/NMO; i katalizator je TEMPO ili TEMPO analog.
The process of claim 3, wherein in step (a-1) compound 1-2 can be prepared via a hydrogensulfite adduct. 
Postupak prema patentnom zahtjevu 3, naznačen time što se u koraku (a-1) spoj 1-2 može pripremiti preko hidrogensulfitnog adukta.
The process of claim 1 or 2, wherein the dynamic kinetic reduction KRED enzyme in step (a-2) comprises the amino acid sequence set forth in SEQ ID NO.1 or an active fragment thereof. 
Postupak prema patentnom zahtjevu 1 ili 2, naznačen time što enzim dinamičke kinetičke redukcije KRED u koraku (a-2) sadrži aminokiselinsku sekvencu navedenu u SEQ ID NO.1 ili njezin aktivni fragment.
The process of claim 1 or 2, wherein a cofactor recycling system is present in step (a-2). 
Postupak prema patentnom zahtjevu 1 ili 2, naznačen time što je sustav recikliranja kofaktora prisutan u koraku (a-2).
The process of claim 1 or 2, wherein the reaction in step (a-2) is carried out in a solvent selected from the group consisting of 2-propanol, sec-butanol, iso-butanol, DMSO, DMF, DMAc, and NMP, and combinations thereof. 
Postupak prema patentnom zahtjevu 1 ili 2, naznačen time što se reakcija u koraku (a-2) provodi u otapalu koje se bira iz skupine koju čine 2-propanol, sec-butilni alkohol, izo-butanol, DMSO, DMF, DMAc, i NMP, i njihove kombinacije.
The process of claim 1 or 2, wherein the reaction in step (b-2) is carried out in the presence of a solvent selected from the group consisting of THF, IPA, MeOH, EtOH, n-PrOH, NMP, DMF, DMAc, MTBE, CH2Cl2, MeCN, Me-THF, methyl cyclopentyl ether, and toluene, and combinations thereof. 
Postupak prema patentnom zahtjevu 1 ili 2, naznačen time što se reakcija u koraku (b-2) provodi u prisutnosti otapala koje se bira iz skupine koju čine THF, IPA, MeOH, EtOH, n-PrOH, NMP, DMF, DMAc, MTBE, CH2Cl2, MeCN, Me-THF, metil ciklopentil eter, i toluen, te njihove kombinacije.
The process of claim 1 or 2, wherein compound I-5(b) salt reacts in step (c-2) with a base selected from the group consisting of Et3N, i-Pr2NEt, i-Pr2NH, pyridine, lutidine, N-methyl morphine, t-BuOK, t-BuONa, t-BuOLi, NaH, NaHMDS, LiHMDS, and KHMDS to produce compound 1-6-1 through an intramolecular cyclization reaction. 
Postupak prema patentnom zahtjevu 1 ili 2, naznačen time što sol spoja I-5(b) reagira u koraku (c-2) s bazom odabranom iz skupine koja se sastoji od Et3N, i-Pr2NEt, i-Pr2NH, piridin, lutidin, N-metil morfin, t-BuOK, t-BuONa, t-BuOLi, NaH, NaHMDS, LiHMDS, i KHMDS da se reakcijom intramolekularne ciklizacije dobije spoj 1-6-1.
A process comprising the reaction steps as described in claim 1 and further reaction steps for the preparation of a compound of formula (IV) in which 
Postupak koji sadrži korake reakcije kako je opisano u zahtjevu 1 i daljnje reakcijske korake za pripremu spoja s formulom (IV) naznačen time što
is hydrogen, methyl, fluorine or chlorine, preferably hydrogen; and T represents one of the groups T1-T9 listed below, where the bond to the pyrazole head group is marked with an asterisk *, 
je vodik, metil, fluor ili klor, poželjno vodik; i T predstavlja jednu od skupina T1-T9 navedenih u nastavku, gdje je veza na glavnu skupinu pirazola označena zvjezdicom *, ili *-C(=O)-NH- T9; i
Process according to any one of claims 2 to 4, further comprising the steps of: reacting in a Step 5 compound (I) with a cyano-donor to prepare intermediate of formula (6) wherein R1 is optionally halogenated C1-C4-alkyl or optionally halogenated cyclopropyl, preferably methyl; and 
Postupak prema bilo kojem od patentnih zahtjeva 2 do 4, naznačen time što nadalje obuhvaća korake: reakciju u Koraku 5 spoja (I) s cijano-donorom da se dobije intermedijer s formulom (6) pri čemu je po izboru halogenirani C1-C4-alkil ili po izboru halogenirani ciklopropil, poželjno metil; i
reacting in a Step 6 compound (6) with an inorganic strong base in a first hydrolysis step followed by adding an inorganic acid in a second hydrolysis step to prepare intermediate of formula (7) wherein R1 is optionally halogenated C1-C4-alkyl or optionally halogenated cyclopropyl, preferably methyl; and 
reakciju u Koraku 6 spoja (6) s anorganskom jakom bazom u prvom koraku hidrolize nakon čega slijedi dodavanje anorganske kiseline u drugom koraku hidrolize radi pripreme intermedijera s formulom (7) pri čemu je po izboru halogenirani C1-C4-alkil ili po izboru halogenirani ciklopropil, poželjno metil; i
T represents one of the 5-membered heteroaromatics T1-T8 listed below, where the bond to the pyrazole head group is marked with an asterisk *, wherein 
T predstavlja jedan od 5-eročlanih heteroaromatika T1-T8 navedenih u nastavku, gdje je veza na glavnu skupinu pirazola označena zvjezdicom *, pri čemu
to prepare an intermediate of formula (12); and 
da se dobije intermedijer s formulom (12); i
reacting a compound of formula (I) and an azide-donoer to prepare intermediate (14) (herein referred to as Step 11) wherein R1 is as defined for a compound of formula (III); and 
reakciju spoja s formulom (I) i azidnim-donorom da se dobije intermedijer (14) (ovdje se naziva Korak 11) pri čemu R1 je kako je definirano za spoj s formulom (III); i
A method for preparing pharmaceutically acceptable sodium nitrite of claim 1, which comprises the steps of: 
Postupak za pripremu farmaceutski prihvatljivog natrijevog nitrita iz zahtjeva 1, naznačen time da sadrži sljedeće korake:
contacting sodium nitrite with water at a first temperature of 45 to 55 °C under inert atmosphere; 
kontakta natrijevog nitrita s vodom pri prvoj temperaturi od 45 do 55 ° C u inertnoj atmosferi;
contacting the water containing sodium nitrite with an activated carbon; 
kontakta vode koja sadrži natrijev nitrit s aktivnim ugljenom;
Sodium nitrite of claim 1 for use in a method of treating a cardiovascular disease, a respiratory disease, a skin disease, cyanide poisoning, or hydrogen sulfide poisoning. 
Natrijev nitrit iz zahtjeva 1, naznačen time da se upotrebljava u postupku liječenja kardiovaskularne bolesti, respiratorne bolesti, kožne bolesti, trovanja cijanidom ili trovanja vodikovim sulfidom.
Sodium nitrite of claim 1 for use in a method of stimulating the growth of new blood vessels. 
Natrijev nitrit iz zahtjeva 1, naznačen time da je namijenjen uporabi u postupku poticanja rasta novih krvnih žila.
An intrauterine delivery system comprising Indomethacin and Levonorgestrel, characterized in that the Indomethacin is contained in the frame material and that levonorgestrel is contained in a silicon based reservoir attached to the frame, wherein the frame consist of ethinylvinylacetate copolymer with 16 % vinylacetate content (EVA 5). 
Intrauterini sustav za isporuku, koji sadrži indometacin i levonorgestrel, naznačen time, da je indometacin sadržan u materijalu okvira i da se levonorgestrel nalazi u spremniku na bazi silikona koji je pričvršćen za okvir, naznačen time što okvir sadrži kopolimer etinilvinilacetata sa 16% sadržajem vinilacetata (EVA 5).